UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 61

Sortiert nach

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

British journal of haematology, 2021-03, Vol.192 (6), p.1026-1030

2021

Link zum Volltext

Verfügbarkeit prüfen

Epigenetics in the hematologic malignancies

Haematologica (Roma), 2014-12, Vol.99 (12), p.1772

2014

Link zum Volltext

Verfügbarkeit prüfen

Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B‐acute lymphoblastic leukaemia

British journal of haematology, 2020-10, Vol.191 (1), p.123-126

2020

Link zum Volltext

Verfügbarkeit prüfen

Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes

Blood, 2017-03, Vol.129 (12), p.1685-1690

2017

Link zum Volltext

Verfügbarkeit prüfen

How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?

Blood cancer journal (New York), 2024-03, Vol.14 (1), p.54-54, Article 54

2024

Link zum Volltext

Verfügbarkeit prüfen

Parvovirus B19–induced pure red cell aplasia in a heart transplant recipient

Blood, 2012-10, Vol.120 (17), p.3395-3395

2012

Link zum Volltext

Verfügbarkeit prüfen

P1212: RATIONALLY DESIGNED CHIMERIC PI3K‐BET BROMODOMAIN INHIBITORS ELICIT CURATIVE RESPONSES IN MYC‐DRIVEN LYMPHOMA

HemaSphere, 2023-08, Vol.7 (S3), p.e4369469-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

BET inhibitor resistance emerges from leukaemia stem cells

Nature (London), 2015-09, Vol.525 (7570), p.538-542

2015

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy

Journal of clinical oncology, 2020-10, Vol.38 (30), p.3506-3517

2020

Link zum Volltext

Verfügbarkeit prüfen

Intensified Induction Chemotherapy Results in More Rapid Early NPM1 Mutant (mut) Measurable Residual Disease (MRD) Clearance but Similar Disease Outcomes

Blood, 2022-11, Vol.140 (Supplement 1), p.6258-6259

2022

Link zum Volltext

Verfügbarkeit prüfen

Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system

Leukemia research, 2022-02, Vol.113, p.106786-106786, Article 106786

2022

Link zum Volltext

Verfügbarkeit prüfen

Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system

Leukemia research, 2022-01, Vol.112, p.106748-106748, Article 106748

2022

Link zum Volltext

Verfügbarkeit prüfen

Erratum to ‘Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system’ [Leukemia Research 112C (2022) 106748]

Leukemia research, 2022-04, Vol.115, p.106784, Article 106784

2022

Link zum Volltext

Verfügbarkeit prüfen

High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial

Blood, 2022-11, Vol.140 (Supplement 1), p.1708-1710

2022

Link zum Volltext

Verfügbarkeit prüfen

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.1453-1455

2022

Link zum Volltext

Verfügbarkeit prüfen

Lemzoparlimab (lemzo) with venetoclax (ven) and/or azacitidine (aza) in patients (pts) with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS): A phase 1b dose escalation study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS7067-TPS7067

2022

Link zum Volltext

Verfügbarkeit prüfen

Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study

Leukemia research, 2024-05, Vol.140, p.107480, Article 107480

2024

Link zum Volltext

Verfügbarkeit prüfen

Measurable Residual Disease (MRD) detection by Next Generation Sequencing (NGS) in Acute Lymphoblastic LEUKAEMIA (ALL)

Pathology, 2020-02, Vol.52, p.S108-S108

2020

Link zum Volltext

Verfügbarkeit prüfen

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Blood, 2021-11, Vol.138 (Supplement 1), p.1261-1261

2021

Link zum Volltext

Verfügbarkeit prüfen

A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC)

Blood, 2019-11, Vol.134 (Supplement_1), p.2652-2652

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase 3, randomized study of pracinostat (PRAN) in combination with azacitidine (AZA) versus placebo in patients ≥18 years with newly diagnosed acute myeloid leukemia (AML) unfit for standard induction chemotherapy (IC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS7078-TPS7078

2018

Link zum Volltext

Verfügbarkeit prüfen

Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study

Leukemia, 2023-05, Vol.37 (5), p.1092-1102

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(58)

Publikationsform

Artikel
(60)
Bücher
(1)

Sprache

Englisch
(61)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Life Sciences & Biomedicine
(21)
Humans
(18)
Hematology
(15)
Oncology
(9)
Female
(8)
Leukemia
(8)
Leukemia, Myeloid, Acute - Drug Therapy
(8)
Male
(7)
Leukemia, Myeloid, Acute - Genetics
(6)
Adult
(5)
Aged
(5)
Animals
(5)
Mice
(5)
Middle Aged
(5)
Cell Line, Tumor
(4)
Adolescent
(3)
Aged, 80 And Over
(3)
Aml
(3)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

Epigenetics in the hematologic malignancies

Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B‐acute lymphoblastic leukaemia

Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population

How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?

Parvovirus B19–induced pure red cell aplasia in a heart transplant recipient

P1212: RATIONALLY DESIGNED CHIMERIC PI3K‐BET BROMODOMAIN INHIBITORS ELICIT CURATIVE RESPONSES IN MYC‐DRIVEN LYMPHOMA

S213: BMS‐986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE‐ OR HIGH‐RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY

BET inhibitor resistance emerges from leukaemia stem cells

Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy

Intensified Induction Chemotherapy Results in More Rapid Early NPM1 Mutant (mut) Measurable Residual Disease (MRD) Clearance but Similar Disease Outcomes

Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system

Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system

Erratum to ‘Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system’ [Leukemia Research 112C (2022) 106748]

High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Lemzoparlimab (lemzo) with venetoclax (ven) and/or azacitidine (aza) in patients (pts) with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS): A phase 1b dose escalation study

Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study

Measurable Residual Disease (MRD) detection by Next Generation Sequencing (NGS) in Acute Lymphoblastic LEUKAEMIA (ALL)

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC)

A phase 3, randomized study of pracinostat (PRAN) in combination with azacitidine (AZA) versus placebo in patients ≥18 years with newly diagnosed acute myeloid leukemia (AML) unfit for standard induction chemotherapy (IC)

Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study

Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

Suchergebnisse filtern